Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240097 · ClinicalTrials.gov registry record · Phase 2
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00240097 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants.
The verdict
NCT00240097, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive small cell lung cancer. The primary objective of Part II of the study is to determine the objective tumor response rate of irinotecan/oxaliplatin in patients with either refractory disease or who have relapsed to first line chemotherapy or chemoradiotherapy.
Interventions
- DRUG Intervention A: Irinotecan; Oxaliplatin; Neulasta
- DRUG Intervention B: Etoposide; Carboplatin; Neulasta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240097
The ClinicalTrials.gov registry entry for NCT00240097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intervention A: Irinotecan; Oxaliplatin; Neulasta is the first listed.
NCT00240097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240097 about?
NCT00240097 is a clinical study titled "Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)". The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive small cell lung cancer. The primary objective of Part II of the study is...
What is the current status of trial NCT00240097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00240097?
The interventions under investigation include: Intervention A: Irinotecan; Oxaliplatin; Neulasta (DRUG), Intervention B: Etoposide; Carboplatin; Neulasta (DRUG).
Who is sponsoring clinical trial NCT00240097?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.